Abstract
Chronic low-grade subclinical inflammation has been increasingly recognized as an interposer in the endocrine, metabolic and reproductive disturbances that characterize the polycystic ovary syndrome (PCOS). Abdominal adiposity and obesity are often present in PCOS. Mounting evidence indicates that adipose tissue is involved in innate and adaptive immune responses. Continuous release of inflammatory mediators such as cytokines, acute phase proteins, and adipokines perpetuates the inflammatory condition associated with obesity in women with PCOS, possibly contributing to insulin resistance and other long-term cardiometabolic risk factors. Genetic variants in the genes encoding inflammation-related mediators underlie the development of PCOS and their interaction with environmental factors may contribute to the heterogeneous clinical phenotype of this syndrome. In the future, strategies ameliorating inflammation may prove useful for the management of PCOS and associated conditions.
Keywords: Polycystic ovary syndrome, androgen excess, hyperandrogenism, inflammation, endothelial dysfunction, insulin resistance, abdominal adiposity, obesity.
Current Pharmaceutical Design
Title:Mediators of Low-Grade Chronic Inflammation in Polycystic Ovary Syndrome (PCOS)
Volume: 19 Issue: 32
Author(s): Miriam Ojeda-Ojeda, Mora Murri, Maria Insenser and Hector F. Escobar-Morreale
Affiliation:
Keywords: Polycystic ovary syndrome, androgen excess, hyperandrogenism, inflammation, endothelial dysfunction, insulin resistance, abdominal adiposity, obesity.
Abstract: Chronic low-grade subclinical inflammation has been increasingly recognized as an interposer in the endocrine, metabolic and reproductive disturbances that characterize the polycystic ovary syndrome (PCOS). Abdominal adiposity and obesity are often present in PCOS. Mounting evidence indicates that adipose tissue is involved in innate and adaptive immune responses. Continuous release of inflammatory mediators such as cytokines, acute phase proteins, and adipokines perpetuates the inflammatory condition associated with obesity in women with PCOS, possibly contributing to insulin resistance and other long-term cardiometabolic risk factors. Genetic variants in the genes encoding inflammation-related mediators underlie the development of PCOS and their interaction with environmental factors may contribute to the heterogeneous clinical phenotype of this syndrome. In the future, strategies ameliorating inflammation may prove useful for the management of PCOS and associated conditions.
Export Options
About this article
Cite this article as:
Ojeda-Ojeda Miriam, Murri Mora, Insenser Maria and Escobar-Morreale F. Hector, Mediators of Low-Grade Chronic Inflammation in Polycystic Ovary Syndrome (PCOS), Current Pharmaceutical Design 2013; 19 (32) . https://dx.doi.org/10.2174/1381612811319320012
DOI https://dx.doi.org/10.2174/1381612811319320012 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
The Role of Autophagy in the Pathogenesis of Ischemic Stroke
Current Neuropharmacology CCR2 Antagonists
Current Topics in Medicinal Chemistry Psychotropics and Methadone in Acquired Long QT Syndrome
Current Psychopharmacology Cardiovascular-Related
Current Bioactive Compounds Mechanisms for Antiplatelet Action of Statins
Current Drug Targets - Cardiovascular & Hematological Disorders Chemical Constituents of the Genus Prunus and their Medicinal Properties
Current Medicinal Chemistry Metaflammation: Tissue-Specific Alterations of the NLRP3 Inflammasome Platform in Metabolic Syndrome
Current Medicinal Chemistry Classical and Innovative Insulin Sensitizing Drugs for the Prevention and Treatment of NAFLD
Current Pharmaceutical Design Bacterial Cell Wall Compounds as Promising Targets of Antimicrobial Agents II. Immunological and Clinical Aspects
Current Drug Targets Carbonyl-Scavenging Drugs & Protection Against Carbonyl Stress-Associated Cell Injury
Mini-Reviews in Medicinal Chemistry Family History and Preclinical Atherosclerosis
Current Hypertension Reviews Interactive Effect of Cigarette Smoking and Gene Variants for Predisposing to Cardiovascular Disease
Current Pharmaceutical Design The Role of Polyunsaturated Fatty Acids (PUFA) in the Treatment of Dyslipidemias
Current Pharmaceutical Design Editorial (Thematic Issue: Cardiovascular Drug Therapy in Paediatric Age: From Metabolomics to Clinical Practice)
Current Medicinal Chemistry Emerging Strategies and Agents to Lower Cardiovascular Risk by Increasing High Density Lipoprotein Cholesterol Levels
Current Medicinal Chemistry Context-Dependent Regulation of Nrf2/ARE Axis on Vascular Cell Function during Hyperglycemic Condition
Current Diabetes Reviews Pharmacological Therapy in Children with Atrioventricular Reentry: Which Drug?
Current Pharmaceutical Design Effects of Simvastatin on the Metabolism of Fatty Acids in Combined Secondary Prevention of Coronary Heart Disease: Dosage and Gender Differences between the Effects
Cardiovascular & Hematological Disorders-Drug Targets New Insights into the Mechanism of Action of Aspirin in the Prevention of Colorectal Neoplasia
Current Pharmaceutical Design Cannabinoids and Schizophrenia: Therapeutic Prospects
Current Pharmaceutical Design